- Home
- LIXT vs QLGN Comparison
LIXT vs QLGN Comparison
Compare LIXT & QLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LIXT
- QLGN
- Stock Information
- Founded
- LIXT 2005
- QLGN 1996
- Country
- LIXT United States
- QLGN United States
- Employees
- LIXT N/A
- QLGN N/A
- Industry
- LIXT Biotechnology: Pharmaceutical Preparations
- QLGN Biotechnology: Pharmaceutical Preparations
- Sector
- LIXT Health Care
- QLGN Health Care
- Exchange
- LIXT Nasdaq
- QLGN Nasdaq
- Market Cap
- LIXT 2.2M
- QLGN 2.3M
- IPO Year
- LIXT N/A
- QLGN N/A
- Fundamental
- Price
- LIXT $4.00
- QLGN $3.38
- Analyst Decision
- LIXT
- QLGN
- Analyst Count
- LIXT 0
- QLGN 0
- Target Price
- LIXT N/A
- QLGN N/A
- AVG Volume (30 Days)
- LIXT 6.2M
- QLGN 17.2K
- Earning Date
- LIXT 08-07-2025
- QLGN 08-13-2025
- Dividend Yield
- LIXT N/A
- QLGN N/A
- EPS Growth
- LIXT N/A
- QLGN N/A
- EPS
- LIXT N/A
- QLGN N/A
- Revenue
- LIXT N/A
- QLGN N/A
- Revenue This Year
- LIXT N/A
- QLGN N/A
- Revenue Next Year
- LIXT N/A
- QLGN N/A
- P/E Ratio
- LIXT N/A
- QLGN N/A
- Revenue Growth
- LIXT N/A
- QLGN N/A
- 52 Week Low
- LIXT $0.64
- QLGN $2.85
- 52 Week High
- LIXT $4.45
- QLGN $29.44
- Technical
- Relative Strength Index (RSI)
- LIXT 80.89
- QLGN 44.06
- Support Level
- LIXT $2.02
- QLGN $3.15
- Resistance Level
- LIXT $4.25
- QLGN $3.99
- Average True Range (ATR)
- LIXT 0.54
- QLGN 0.25
- MACD
- LIXT 0.30
- QLGN 0.00
- Stochastic Oscillator
- LIXT 96.99
- QLGN 27.94
About LIXT Lixte Biotechnology Holdings Inc.
Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.
About QLGN Qualigen Therapeutics Inc.
Qualigen Therapeutics Inc is an early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's program, QN-302, is an investigational small-molecule G-quadruplexes (G4)-selective transcription inhibitor with binding affinity to G4s prevalent in cancer cells.